Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Keya Medical Closes $22 Million Funding for AI Imaging Software

publication date: Aug 21, 2020

Beijing Keya Medical Technology closed a $22 million Series B+ funding round to support its AI-based cardiovascular imaging software. The company's headquarters is in Seattle, where it is known a CuraCloud, though all of the company's capital has come from China investors. In China, it has operations in Beijing and Shenzhen. Earlier this year, Keya closed a $14 million B financing. The B+ round was led by GGV Capital, and it included existing investors Kunlun, Shanghai International Group and Yahui Capital. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital